

~~Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.~~

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 2

Complete if Known

Application Number	10/601,205
Filing Date	June 20, 2003
First Named Inventor	H. Duetmann
Art Unit	1614
Examiner Name	To be assigned
Attorney Docket Number	1/1362

U. S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ²
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)				
VA		WO 9732585	09/12/1997	Medinox, Inc.		
VA		SU 1084024	04/07/1984	Leningrad Research Inst. of Vaccines and Sera		
VA		GB 872146	07/05/1961	I. Innerfield		

Examiner Signature	V. Afremova	Date Considered	5-06-2005
-----------------------	-------------	--------------------	-----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



PTO/SB/08b (08-03)
Approved for use through 06/30/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete If Known	
				Application Number	10/601,205
				Filing Date	June 20, 2003
				First Named Inventor	H. Duetmann
				Art Unit	1614
				Examiner Name	To be assigned
Sheet	2	of	2	Attorney Docket Number	1/1362

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
VA		Database WPI, Section Ch, Week 198447, Derwent Publications Ltd., London, GB; Class B04, AN 1984-293724 XP002257350 & SU 1 084 024 A (Lengd Vaccine Sera), 04/07/1984	
↑		Hacke, W. et al: "Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II)" <i>Lancet</i> , XX, XX, Volume 352, Number 9136, Oct. 17 1998, Pages 1245-1251, XP004265690, ISN: 0140-6736	
		Nagai, N. et al: "Comparative effects of tissue plasminogen activator, streptokinase, and staphylokinase on cerebral ischemic infarction and pulmonary clot lysis in hamster models" <i>Circulation</i> , Vol. 100, No. 25, Dec. 21, 1999, Pages 2541-2546, XP002258347, ISSN: 009-7322	
		Serrano, Ramon L. et al: "ATP-regulated activity of the plasmin-streptokinase complex: A novel mechanism involving phosphorylation of streptokinase" <i>Biochemical Journal</i> , Vol. 313, No. 1, 1996, Pages 171-17, XP002257347, ISSN: 0264-6021, Page 176	
		Foster, Thomas M. et al: "Thermal stability of low molecular weight urokinase during heat treatment: III. Effect of salts, sugars and tween 80: <i>International Journal of Pharmaceutics</i> (Amsterdam), Vol. 134, No. 1-2, 1996, pages 193-201 XP002257348, ISSN: 0378-5173, page 197, page 200	
VA		ROTE Liste Service GmbH: "Rote Liste 1997", 1997, ECV - Editio Cantor - Aulendorf/Wuerth, Frankfurt/Main XP002257349 - with translation	

Examiner Signature	<i>V. Afenise</i>	Date Considered	5-06-2005
-----------------------	-------------------	--------------------	-----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.
This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.